Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunitybio Inc (NQ: IBRX )

7.990 -1.000 (-11.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,004,117
Open 8.880
Bid (Size) 7.800 (5)
Ask (Size) 7.900 (54)
Prev. Close 8.990
Today's Range 7.900 - 9.390
52wk Range 1.250 - 10.53
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Check Out What Whales Are Doing With IBRX
Via Benzinga
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
From ImmunityBio, Inc.
Via Business Wire

Performance

YTD
+52.48%
+52.48%
1 Month
+50.19%
+50.19%
3 Month
+126.99%
+126.99%
6 Month
+154.46%
+154.46%
1 Year
+159.42%
+159.42%

More News

Read More
Stocks Quietly Climb Ahead Of Central Bank Storm
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Philips Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
What's Going On With ImmunityBio Stock?
Via Benzinga
ImmunityBio: Q4 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Teradyne Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
FDA Approves ImmunityBio's Bladder Cancer Drug, Stock Rallies
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
From ImmunityBio, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
Via FinancialNewsMedia
5 Stocks with Unusually Large Short Interest
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
From ImmunityBio
Via Business Wire
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
From ImmunityBio
Via Business Wire
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.